Discontinued — last reported Q4 '25

Non-Current Liabilities

Finance Lease Liabilities (Total)

West Pharmaceutical Services Finance Lease Liabilities (Total) decreased by 5.9% to $4.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.3%, from $4.20M to $4.80M. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ1 2019
Last reportedQ4 2025

How to read this metric

An increase indicates higher reliance on lease-based financing for long-term assets, which increases fixed financial obligations and leverage ratios.

Detailed definition

This represents the present value of future lease payments for assets where the lease term covers a major part of the as...

Peer comparison

Comparable to debt obligations, this metric is analyzed alongside long-term borrowings to assess the total capital structure and financial risk profile of peer energy companies.

Metric ID: finance_lease_liabilities_total

Historical Data

10 periods
 Q4 '21Q4 '22Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0.00$0.00$3.30M$3.10M$3.00M$4.20M$4.90M$5.40M$5.10M$4.80M
QoQ Change-6.1%-3.2%+40.0%+16.7%+10.2%-5.6%-5.9%
YoY Change+48.5%+74.2%+70.0%+14.3%
Range$0.00$5.40M
Avg YoY Growth+51.7%
Median YoY Growth+59.2%
Current Streak2 quarters decline

Finance Lease Liabilities (Total) at Other Companies

Frequently Asked Questions

What is West Pharmaceutical Services's finance lease liabilities (total)?
West Pharmaceutical Services (WST) reported finance lease liabilities (total) of $4.80M in Q1 2026.
How has West Pharmaceutical Services's finance lease liabilities (total) changed year-over-year?
West Pharmaceutical Services's finance lease liabilities (total) increased by 14.3% year-over-year, from $4.20M to $4.80M.
What does finance lease liabilities (total) mean?
The total present value of future payments for leased assets that are essentially treated as debt-financed purchases.